Although probable, I feel this is unlikely given the amount of new research going into RNA epigenetic modification.
accent therapeutics formed a partnership for this reason, as they're purely an RNA epigenetic modification company.
given how far advanced we are in this space(as Dr T put it, we have a 50m headstart in a 100m race), the board wouldn't advise us to get bought out without taking into consideration pillar I. And I doubt a big pharma would drop a massive potential in targeted oncology, given the amount of revenue it may achieve.
Oncology - Pharma Deals News, page-154
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |